"10.1371_journal.pone.0032369","plos one","2012-03-06T00:00:00Z","Nikos Pantazis; Charles Morrison; Pauli N Amornkul; Charlotte Lewden; Robert A Salata; Albert Minga; Tsungai Chipato; Harold Jaffe; Shabir Lakhi; Etienne Karita; Kholoud Porter; Laurence Meyer; Giota Touloumi; on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group","Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece; FHI 360, Durham, North Carolina, United States of America; International AIDS Vaccine Initiative (IAVI), San Francisco, California, United States of America; Université Victor Segalen Bordeaux 2, ISPED, Bordeaux, France; Case Western Reserve University, Cleveland, Ohio, United States of America; Programme PAC-CI, Abidjan, Côte dIvoire; University of Zimbabwe, Harare, Zimbabwe; University of Oxford, Oxford, United Kingdom; Zambia Emory HIV Research Project (ZEHRP), Lusaka, Zambia; Project San Francisco, Kigali, Rwanda; Medical Research Council Clinical Trials Unit, London, United Kingdom; Inserm, U1018, HIV Epidemiology, Université Paris-Sud, AP-HP, Le Kremlin-Bicêtre, France; Inserm, U897, Bordeaux, France","¶ Membership of the CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group is provided in the Acknowledgments.","The authors have declared that no competing interests exist.","2012","03","Nikos Pantazis","NP",14,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
